Pharmstandard of Russia Sees Sharp Revenue Rise From Selling J&J Drug
This article was originally published in PharmAsia News
Executive Summary
Russia's leading pharmaceutical company, Pharmstandard, credited its marketing of Johnson & Johnson's Velcade (bortezomib) cancer drug for producing a third of its $469.3 million in revenues during its third quarter, close to double the previous year.